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Epstein-Barr virus (EBV) is a double stranded DNA virus
belonging to the family of herpesviruses. It can infect B lym-
phocytes as well as malignant cells of several lineages, includ-
ing T lymphocytes, epithelial cells, and smooth muscle cells.
EBV is associated with a wide range of malignancies, including
posttransplant lymphoproliferative disorder (PTLD), Hodgkin
and non-Hodgkin lymphomas, nasopharyngeal carcinoma, gas-
tric carcinoma, and leiomyosarcoma.
Nearly every human is infected before adulthood. Infection
early in childhood is usually asymptomatic, while delayed pri-
mary infection is typically manifest by the signs and symptoms
of infectious mononucleosis. Once infection occurs, the viral
genome is maintained for life in a small fraction of B lympho-
cytes. Periodic reactivation of the virus occurs in the oral mu-
cosa, where shedding of virions in saliva propagates the infec-
tion among human hosts.
Systemic reactivation of an infection is normally kept in
check by the healthy immune system that fights lytic replication
using cytotoxic T lymphocytes, natural killer cells, and anti-
body-dependent cell cytotoxicity. The virus persists long-term
as a latent infection. EBV is capable of driving B cell prolif-
eration in vitro to form immortalized cell lines and also in vivo
when immune surveillance is inadequate (119, 179). In the
setting of allogeneic transplantation when iatrogenic immuno-
suppression is used to prevent graft rejection, an unintended
consequence is failure to suppress active EBV infection, which
is accompanied by a heightened risk of developing PTLD (7,
61, 154, 167, 185, 198). PTLD is a potentially life-threatening
neoplasm exhibiting a spectrum of histopathologies ranging
from reactive-appearing, polyclonal lymphoid infiltrates to
sheets of undifferentiated cells that are morphologically indis-
tinguishable from malignant lymphoma or plasma cell my-
eloma. PTLD is nearly always EBV related, meaning that EBV
DNA lies within the nuclei of the proliferating lymphocytes.
Elevated levels of EBV DNA are present in blood specimens
of affected patients, including intracellular EBV within circu-
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lating B lymphocytes and extracellular EBV DNA measurable
in plasma (77). EBV load, as measured by quantitative molec-
ular analysis of the viral genome, serves as a biomarker for
predicting and monitoring the course of PTLD (77).
While tumorigenesis is multifactorial, the nearly constant
presence of the EBV within the lymphoproliferative lesion
implies that EBV drives the process. Since similar EBV-driven
lymphoproliferations are seen in other immunosuppressive set-
tings, such as chemotherapy-related immunosuppression for
autoimmune disease or age-related decline in immunity, it
appears that impaired immunity is the other major tumorigenic
cofactor beyond EBV infection (119, 126, 187). In particular,
diminished T cell immunity allows uncontrolled infection, which
can progress rapidly and systemically if not promptly recog-
nized and treated. Lesional tissue contains EBV-infected cells
that are almost always monoclonal, as shown by clonal immu-
noglobulin (IGH) gene rearrangement, by clonal EBV ge-
nomes, or by monotypic expression of kappa or lambda light
chains (76, 96). It is thought that the tumor arises as an out-
growth of a single infected cell, either a donor B cell in a
patient who underwent allogeneic stem cell/marrow transplant
or a recipient B cell in a patient who underwent solid organ
transplant (163). Undoubtedly, secondary genetic events mark
the neoplastic transformation (194).
Clinical Presentation of PTLD
PTLD typically occurs in the first year after transplantation,
sometimes within weeks of the onset of immunosuppression.
The median onset of PTLD is 2 months after marrow trans-
plant or 6 months after solid organ transplant. Onset is delayed
occasionally beyond a year and rarely beyond a decade after
transplantation.
Symptoms are often quite nonspecific, e.g., fever, malaise, and
anorexia (190), and some patients are asymptomatic. PTLD fre-
quently presents as a rapidly enlarging mass in the grafted
organ, in lymph nodes, filling the marrow space, or in extra-
nodal sites such as upper airway or intestine.
In young children, primary EBV infection often occurs after
iatrogenic immunosuppression commences, either when an in-
fected graft is introduced or later in the posttransplant period.
Although the infection is primary, one is cautioned against mak-
ing a diagnosis of infectious mononucleosis, since that diagnosis
implies a self-limited process, whereas an immunosuppressed
transplant recipient requires vigilant monitoring of the infection.
PTLD can present with symptoms reminiscent of infectious
mononucleosis, but PTLD is a much more serious illness.
RISK FACTORS FOR PTLD
Nearly all transplant recipients are infected or eventually
become infected by EBV, yet only a fraction will develop
PTLD. Risk factors for PTLD are as follows: EBV seronega-
tivity at the time of transplant, active primary EBV infection at
the time of transplant, underlying disease leading to transplan-
tation, prior splenectomy, second transplant, patient age (chil-
dren and older adults), coinfection by cytomegalovirus and
other viruses, acute or chronic graft-versus-host disease, im-
munosuppressive drug regimen and intensity, cytokine poly-
morphisms, HLA type and extent of HLA mismatch, and the
presence of multiple risk factors on this list. In a study by
Landgren et al. of 21,686 stem cell transplant patients (104), a
low incidence of PTLD (0.2%) was found in patients with no
risk factors, while the incidence was 8.1% when there were
three or more risk factors for PTLD. Incidence also varies by
the organ that was transplanted (Table 1.)
A major predisposing factor is EBV seronegativity at the time
of solid organ transplant, with young children being most likely to
have avoided exposure to EBV prior to transplantation (139).
Interestingly, advanced age was also a risk factor for PTLD
among renal and stem cell transplant recipients (23). Active pri-
mary EBV infection is a contraindication to transplantation (11).
A critical risk factor is the drug regimen used to prepare the
patient for transplant as well as the ongoing immunosuppres-
sive drugs used to prevent graft rejection (122, 142). For ex-
ample, anti-thymocyte globulin depletes T cells and thus pro-
tects from graft rejection, but its use clearly contributes to
subsequent PTLD (104, 105, 172). Fludarabine, azathioprine,
and other agents causing profound T cell suppression or mu-
tagenicity are also implicated in PTLD pathogenesis (99, 119,
172). Ironically, agents diminishing both B and T cell immunity
are not as problematic (104). Patients having multiple bouts of
rejection with corresponding interventions to heighten immu-
nosuppression may be at higher risk of PTLD.
Particular HLA types influence recognition of cells express-
ing foreign viral proteins, which in turn influences the patho-
genesis of EBV-driven lymphoproliferation (66, 179, 208). For
example, the HLA-A3 allele is associated with a sevenfold risk
of PTLD among patients who were seronegative at the time of
lung transplantation (208). It is suggested that HLA type in-
fluences the immune system’s ability to present certain foreign
epitopes for immune destruction. Recently, there is increased
acknowledgment of the role of host cytokine polymorphisms
(e.g., mutated gamma interferon [IFN-], transforming growth
factor  [TGF-], and interleukin-10 [IL-10]) in defense
against EBV and other viral pathogens (13, 80, 108, 179).
Likewise, EBV genomic polymorphism is emerging as a po-
tential contributor to tumorigenesis (51, 74, 118, 165, 199).
Variants in viral LMP1 gene sequence have been linked to
pathogenesis and severity of lymphoid neoplasia (74, 165).
HISTOLOGIC FEATURES, IMMUNOPHENOTYPE,
AND GENETICS
PTLD is divided into four major histopathologic subtypes
with corresponding clinical and biologic features (28), as de-
scribed in the World Health Organization (WHO) subclassifi-
cation scheme (187). These include early lesions, polymorphic






Kidney 0.5–1 1–10 18, 100, 127, 190
Marrow and stem cell 0.5–1 13 104, 116, 183
Liver 1.6–5 4–15 59, 93, 100, 210
Heart or lung 1.9–10 6–20 100, 171
Intestinal 12 100, 152
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PTLD, monomorphic PTLD, and classical Hodgkin lymphoma-
type PTLD (Fig. 1). Although these lesions may bear micro-
scopic resemblance to diseases arising sporadically in other-
wise healthy individuals (e.g., infectious mononucleosis, diffuse
large B cell lymphoma, myeloma, Hodgkin lymphoma, and
age-related B cell lymphoproliferative disorder), their occur-
rence in the setting of transplantation warrants a diagnosis of
PTLD given that the natural history and recommended ther-
apy for PTLD differ from those for lesions having similar
histologic features in nonimmunocompromised hosts. In terms
of natural history, PTLD almost always progresses quite rap-
idly to a fatal conclusion unless promptly recognized and
treated (141). The ability to reduce or eliminate immunosup-
pressive drugs is a helpful strategy for restoring natural anti-
viral and antineoplastic immunity.
Early Lesions
Early lesions usually arise within 6 months after graft place-
ment in a seronegative recipient. Unlike other subtypes of
PTLD, early lesions are often polyclonal and exhibit architec-
tural preservation of the affected tissue (188) (Fig. 1A). Re-
ducing immunosuppression allows immune recognition and
control of the EBV-driven B cell proliferation. If untreated, a
single neoplastic clone may emerge to generate a monoclonal
process with eventual histologic progression and effacement of
tissue architecture, signifying a transition to one of the more
advanced subtypes of PTLD described below (188).
Polymorphic PTLD
Polymorphic PTLD is termed polymorphic because of the
mixture of small to large lymphocytes and immunoblasts that
efface lesional tissue by microscopic examination (Fig. 1B).
These cells include EBV-infected neoplastic B cells as well as
reactive CD4 and CD8 T cells. The mitotic rate may be brisk,
and clonality assays reveal monoclonal B cells (77). Reducing
the level of immunosuppression is often but not always effec-
tive in reversing cell growth (14, 171).
Monomorphic PTLD
In monomorphic PTLD there are sheets of atypical lympho-
cytes mimicking one of the conventional histopathologic types
FIG. 1. Histopathologic features reflect clinical subtypes of PTLD. (A) An early lesion (plasmacytic hyperplasia) contains mature polyclonal plasma
cells that expand but do not replace tissue architecture. (B) In polymorphic PTLD there is a mixture of small and large lymphocytes. (C) In monomorphic
PTLD there are sheets of large lymphoid cells reminiscent of diffuse large B cell lymphoma. (D) EBER in situ hybridization reveals a purple EBER signal
localized to the nuclei of tumor cells. (Photomicrographs courtesy of Yuri Fedoriw, University of North Carolina at Chapel Hill; reproduced with
permission.)
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of B cell malignancy, i.e., diffuse large B cell lymphoma, immu-
noblastic lymphoma, Burkitt lymphoma, anaplastic large cell lym-
phoma, or myeloma (Fig. 1C). The immunophenotype usually
demonstrates B cell lineage, although rare cases of T cell or NK
lineage are reported (186). The vast majority of cases are EBV
infected, but occasional cases lack EBV, and these are more likely
to occur late (beyond 1 year) after transplantation (186), implying
that they are akin to lymphoma of the conventional type. Con-
ventional lymphoma therapy is not necessarily needed, however,
since monomorphic PTLD can be managed in some instances by
reducing immunosuppression (67, 100).
Classical Hodgkin Lymphoma-Type PTLD and
Other Rare Variants
Rare cases of classical Hodgkin lymphoma-type PTLD occur
late after transplant (beyond the first year) and invariably con-
tain EBV within the malignant Reed-Sternberg/Hodgkin cells
(148). The immunophenotype is that of nodular sclerosis or
mixed cellularity Hodgkin lymphoma, and response to therapy
is generally favorable (174). Other rare histologies include
primary effusion lymphoma with coinfection by EBV and hu-
man herpesvirus 8 (HHV8), well-differentiated lymphoma
of the marginal zone or mucosa-associated lymphoid tissue
(MALT) subtype, and florid follicular hyperplasia, which could
be an early histologic manifestation of PTLD (195).
Histochemical Stains in Biopsy Specimens
Biopsy is necessary to confirm a diagnosis of PTLD and to
rule out other neoplastic or infectious lesions (11). Histochem-
ical stains are helpful in narrowing the differential diagnosis. In
situ hybridization targeting EBV-encoded RNA (EBER) is the
single best laboratory procedure for localizing EBV to neo-
plastic cells, thus defining a PTLD as an EBV-related neo-
plasm (129) (Fig. 1D). Because RNA is labile, negative EBER
stain results should always be interpreted in the context of a
control assay to demonstrate that RNA is preserved and avail-
able for hybridization. Immunohistochemistry is somewhat less
reliable, since viral proteins such as LMP1, LMP2, EBNA1,
and EBNA2 may be expressed focally or inconsistently in
PTLD cases with EBV infection (40, 175).
B Cell Lineage and Viral Reprogramming
CD20 stains are typically positive in PTLD, consistent with B
cell lineage and predicting response to anti-CD20 antibody
therapy. Interestingly, some cases of PTLD lack CD20 expres-
sion, and it is hypothesized that downregulation of CD20 and
other B cell markers occurs in response to EBV infection (8,
170). An analogous process is thought to account for virus-
mediated reprogramming of the B cell phenotype in classical
Hodgkin lymphomas (176). Immunotherapy specifically target-
ing B cells, such as anti-CD20 antibody therapy, might be
ineffective when the B cell phenotype is reprogrammed
(170). Likewise, EBV may interfere with programmed cell
death in B cells, potentially contributing to viral persistence,
accumulation of somatic mutations, and neoplastic transfor-
mation (20, 21, 27, 169, 189).
Viral Gene Expression Patterns
To evade immune destruction and promote lifelong persis-
tence of viral infection, EBV gene expression is normally re-
stricted to nonimmunogenic factors such as EBER transcripts
and microRNAs (type 0 latency) that can inhibit apoptosis (39,
46, 88, 132). Some mucosal B lymphocytes additionally express
EBNA1 (type 1 latency), which maintains the EBV genome
and ensures its propagation to dividing cells (209), and LMP1
and LMP2 (type II latency), which mimic B cell receptor stim-
ulation with JAK/STAT signaling to promote cell proliferation,
inhibit apoptosis, and generate long-lived memory B cells
(22, 200). In PTLD, neoplastic cells often express an even
wider range of viral factors, including those listed above plus
EBNA-2, -3A, -3B, -3C, and -LP (type III latency), which are
associated with NF-B activation, MYC upregulation, major
histocompatibility complex (MHC) class 1 repression, and
rapid cell proliferation (9, 40, 54, 120, 132, 175). Each cell
division is accompanied by susceptibility to secondary genetic
mutation that could further promote clonal neoplastic cell
growth (73).
Acquired Mutations
The genetic alterations driving neoplastic cell growth are not
well characterized (195). Karyotype and comparative genomic
hybridization studies reveal acquired gross chromosomal de-
fects in about half of PTLD cases (42, 149, 156, 195). Mutation
or rearrangement of BCL6 (3q27), MYC (8q24), PAX5 (9p13),
PIM1 (6p21), RHOH (4p13), or NRAS (1p13) may relate, at
least in part, to somatic hypermutation occurring naturally in B
cells (27, 42, 136, 149, 194, 195). Methylation-induced inacti-
vation of tumor suppressor genes (DAPK1 and MGMT) has
also been described (24, 35, 159). These genetic defects seem
to arise in a background of chronic inflammation that, in turn,
is caused by graft versus host disease, various infections, acute
or chronic rejection, and other inflammatory processes typical
of transplant recipients. Gene expression profiling reveals dif-
ferent patterns of human gene transcription in EBV-positive
and EBV-negative patients (35). Notable differences include
overexpression of interferon-regulated factors and downregu-
lation of B cell receptor signaling molecules in virus-infected
tumors. The differences suggest that EBV is not an innocent
bystander but rather is associated with specific biochemical
alterations promoting evasion of immune recognition, prolif-
eration, and persistence (35). The PTLD profile is distinct
from that of B cell lymphomas and is similar to that of memory
or activated B cells (194).
EBV LOAD AS A MARKER OF PTLD
EBV viral load measurement has become a routine test for
monitoring transplant recipients at high risk of PTLD or under
therapy for PTLD. PTLD patients nearly always have high
levels of EBV DNA in whole blood and in plasma (206).
Indeed, high circulating EBV levels serve as a measure of
tumor burden that can be monitored during treatment (67, 68,
193, 196, 197, 206). Even before the onset of signs and symp-
toms, high EBV levels serve as a harbinger of impending
PTLD, thus permitting preemptive intervention to avert illness
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and halt disease progression (2, 15, 36, 69, 71, 99, 109, 131, 137,
143, 172, 185, 197) (Fig. 2).
While high EBV loads are seen in nearly all patients with
PTLD, less-marked elevations in viral load may be seen in
healthy recipients (e.g., immunosuppressed transplant patients
without PTLD or incipient PTLD), emphasizing the impor-
tance of using a quantitative rather than a qualitative assay to
measure EBV DNA. The literature contains no consistent
number or threshold corresponding to the term “high EBV
load.” Individual testing laboratories have set their own cutoffs
distinguishing PTLD or impending PTLD from baseline viral
loads, but it is difficult to translate these cutoff values across
laboratories because of a lack of international consensus on
the best calibrator, specimen type, or unit of reporting. In one
study, Wagner et al. found that whole blood from PTLD pa-
tients had a median EBV load of 19,200 (range, 6,255 to
171,795) copies/g DNA, while immunosuppressed controls
without serologic evidence of active infection typically had
levels of below 5,000 copies/g DNA. Plasma from PTLD
patients had a median EBV load of 3,225 (range, 1,015 to
4,745) copies/100 l, while controls had fewer than 740 copies/
100 l (206).
In another study, Schubert et al. found six cases of PTLD
among 41 pediatric heart transplant recipients (172). All tu-
mors occurred late after transplant (1.3 to 8.6 years), and these
patients had blood EBV loads of above 2,000 EBV copies/g
of DNA. However, some patients without PLTD also had
levels at least as high. Receiver operator characteristic (ROC)
curve analysis showed sensitivity and specificity values of 100%
and 86% for PTLD using a cutoff of 2,000 copies/g, 100% and
90% for 3,000 copies/g, and 67% and 94% for 5,000 copies/
g. Furthermore, EBV levels were linked to the drug regimen
used for immunosuppression, and changes in drug regimen or
dose were correlated with changes in EBV load (172).
To predict PTLD with greater accuracy, some investigators
suggest calculating a mean viral load over time instead of using
a single cutoff value. A higher mean baseline EBV load cor-
relates with heightened risk of PTLD or recurrent PTLD (7,
19). Other investigators propose combining EBV DNA mea-
surement with a complementary test, such as EBV-specific T
cell enumeration as measured by a peptide tetramer or en-
zyme-linked immunosorbent spot, EBV serology, reverse tran-
scription-PCR (RT-PCR) targeting EBV transcripts, cytokine
gene polymorphism, ATP release, gammopathy by serum pro-
tein electrophoresis, microarray-based expression profiles, and
CD20 or CD4/CD8/NK cell counts (6, 10, 17, 25, 53, 107, 112,
117, 123, 151, 158, 166, 173, 177, 192, 207, 211, 213). Some of
these tests reflect the immune system’s ability to control EBV
infection, while other tests reflect general immune function. At
this time, evidence linking these tests to patient outcomes is
anecdotal. Further research is needed to develop evidence-
based strategies and algorithms predicting PTLD with greater
accuracy. Caution is advised since some test results are mis-
leading in the aftermath of transfusion or other exogenous
influences (e.g., maternal antibodies in infants).
A report by Omar et al. exemplifies current medical practice
and also illustrates the observational nature of investigations in
this field (137). In this single-institution study, 131 consecutive
FIG. 2. EBV load, as measured by quantitative PCR in whole blood or plasma, mirrors clinical status in transplant recipients. Nearly every
human becomes infected during childhood or adolescence, at which time the viral load climbs until the infection is brought under control by the
immune system. Humoral and cell-mediated immunity established during primary infection helps maintain viral quiescence for the remainder of
the person’s life, with latent EBV DNA retained for life in a small subset of B lymphocytes. Healthy carriers have measurable EBV DNA in whole
blood, whereas plasma rarely contains EBV DNA at levels exceeding the lower limit of detection. When a transplant patient is iatrogenically
immunosuppressed to prevent graft rejection, active viral infection results in higher baseline viral loads in both whole blood and plasma. Levels
often rise before clinical diagnosis of posttransplant lymphoproliferation (PTLD), allowing preemptive intervention in high-risk patients who are
routinely monitored for EBV levels. Successful intervention is marked by a return to baseline. A child or a rare adult who was never infected before
onset of iatrogenic immunosuppression lacks prior immunity, placing the patient at high risk for active viral infection and progression to neoplasia.
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stem cell transplant recipients were divided into two groups
based on prior risk factors, with high-risk patients undergoing
EBV load measurement weekly during the first 3 months,
while standard-risk patients underwent testing only when they
were suspected to have EBV infection (which turned out to be
a common scenario). Forty percent of high-risk patients had at
least one positive EBV result, compared to 24% of standard-
risk patients, and median values were elevated in the high-risk
group. Rituximab was given when the EBV load exceeded
10,000 copies per ml of serum or when symptoms suggested
EBV disease, which happened in nine high-risk and three
standard-risk patients. Four patients developed biopsy-proven
PTLD, three in the high-risk group (6%) and one in the stan-
dard-risk group (1%), at a median of 70 days posttransplant.
None of the PTLD cases were missed by the routine monitor-
ing strategy. Two of the four affected patients survived, and
one of those survivors also received cytotoxic T cell infusion.
The authors conclude that routine monitoring of EBV levels
might be useful for purposes of preventing PTLD, and they
recommend a large prospective study (137).
CLINICAL INDICATIONS FOR TESTING
EBV load testing is commonly used to assist in diagnosis and
monitoring of transplant recipients, despite a paucity of clinical
trials demonstrating the utility of EBV DNA measurement in
such settings. Indications for EBV load testing in an immuno-
suppressed transplant recipient typically include lymphade-
nopathy or other mass lesion, organ dysfunction, fever, mal-
aise, or other signs and symptoms suggestive of PTLD. In
addition, routine monitoring of EBV load in high-risk patients
can help identify PTLD before signs and symptoms appear (15,
89, 109, 204). Early diagnosis is critical, as it may prevent
secondary genetic events that render the tumor less treatable
and may permit intervention before organ dysfunction be-
comes irreversible (59, 191). An EBV load above the labora-
tory’s established threshold for PTLD should be conveyed to
the clinician immediately so it may trigger a search for putative
sites of disease followed by biopsy, when reasonable, to estab-
lish a histopathologic diagnosis. Even in the absence of biopsy-
proven PTLD, preemptive intervention may be used to resolve
laboratory-detected disease (3, 60, 110, 185). Preemptive ther-
apy may include reducing immunosuppression and infusing
anti-CD20 antibody or donor T cells.(110) The threshold for
preemptive treatment is reported in a number of prior studies,
and the success of preemption is gauged by a drop in circulat-
ing EBV DNA by at least one log unit within the first week of
intervention (2, 3, 15, 99, 109, 130, 137, 143, 185, 197).
Frequency of EBV Load Testing
Patients at high risk for PTLD (e.g., those who are intensely
immunosuppressed and who were seronegative at the time of
transplant) (89) tend to be monitored frequently (e.g., weekly
in the first few months after transplant and then monthly) so
that preemptive therapy may be considered (11, 67, 71, 91, 99,
137, 185). Preemptive therapies include reducing immunosup-
pression and infusing anti-CD20 antibody or donor T cells (60,
110, 124, 183).
Optimally designed trials should measure EBV load once
monthly during the first year, with some patients continuing to
be frequently monitored beyond the first year if they have a
history of high EBV loads, if their drug regimen is particularly
immunosuppressive, or in the aftermath of discontinuing anti-
viral prophylaxis (36, 67, 91). The European Best Practice
Guidelines for Renal Transplantation recommend using EBV
load to gauge intervention (11). In its practice guidelines, the
“Kidney Disease: Improving Global Outcomes” Transplant
Work Group recommends that high-risk renal transplant pa-
tients be tested for EBV nucleic acid once within the first week
after transplant, then at least monthly for 3 to 6 months, and
then every 3 months for the rest of the first year (96a). Addi-
tional EBV testing is recommended after treatment for acute
rejection (96a). Renal transplant recipients lacking risk factors
for PTLD forego routine monitoring in some centers (89).
Reduced immunosuppression is recommended upon diagnosis
of PTLD and in patients likely to develop PTLD based on
rising EBV levels (96a).
The Second European Conference on Infections in Leuke-
mia issued guidelines calling for routine EBV load testing of
high-risk allogeneic stem cell transplant recipients (185).
Screening should begin the day of transplantation and con-
tinue at least weekly for the first 3 months and even longer if
the patient (i) is being treated for graft-versus-host disease, (ii)
has a haploidentical graft, or (iii) has already experienced EBV
viremia. More frequent testing is worth considering if the
EBV load is rising. The threshold for intervention varies by
local experience; a level of 100 g eq/ml of whole blood or
plasma was suggested in one study (185). It is difficult to
discern how this threshold corresponds to levels measured
by another testing laboratory, further reinforcing the need
for a universal calibrator.
Using EBV Levels To Predict Graft Dysfunction, Rejection,
or Degree of Immunosuppression
Asymptomatic viremia implies a heightened risk for progres-
sion to PTLD and also predicts other adverse outcomes, such as
graft dysfunction, acute rejection, or late-onset PTLD (5, 19, 92,
113). Among heart transplant recipients studied by Bingler et al.,
those with chronic EBV viremia were more likely to develop
late-onset PTLD, occurring as long as 8.4 years after transplant
(19). D’Antiga et al. had similar findings with pediatric liver re-
cipients (36). However, the majority of patients with chronic high
EBV levels do not go on to develop PTLD (36, 70).
Jabs et al. showed that EBV viremia occurring immediately
after renal transplant was associated with subsequent rejection
episodes, and they speculate that T cell responses to viral
infection might cross-react with the graft (92). Li et al. likewise
linked subclinical cytomegalovirus or EBV viremia with rejec-
tion episodes and also with poor long-term renal graft function
or graft loss (114). Interestingly, Ahya et al. showed the oppo-
site effect in lung transplant patients, in whom EBV PCR
positivity correlated with a lower incidence of graft rejection
episodes (5). They speculate that EBV load serves as a func-
tional marker of the degree of immunosuppression and that
undetectable EBV implies underimmunosuppression and as-
sociated risk of rejection (5). A link between viral load and
level of immunosuppression in heart transplant patients was
noted as well (43).
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Modern drug regimens have evolved to strike a balance
between too little and too much immunosuppression, given the
side effects of specific agents combined with the risks of op-
portunistic infection, neoplasia, and organ rejection. Further
research is needed to explore the role of EBV load assays in
monitoring the success of immunosuppressive strategies.
ASSESSING THERAPEUTIC EFFICACY
Clinical management of PTLD typically involves reducing iat-
rogenic immunosuppression so that natural immunity against
EBV and the neoplastic clone is restored (32, 83, 96a, 185). The
power of the immune system is remarkable, given that monoclo-
nal tumors may disappear once immunity is reconstituted (67,
100). However, restoring immunity alone may be insufficient, and
the risk of graft rejection calls for careful consideration of all
available therapies. Complementary interventions include infus-
ing donor lymphocytes (typical healthy donor mononuclear cells
are comprised of about 5% EBV-directed cells) (17), infusing
EBV-specific cytotoxic T cells that are grown ex vivo by exposing
HLA-matched T cells to EBV antigens (37, 64, 79, 85, 168), and
infusing anti-CD20 monoclonal antibody (e.g., rituximab) (33, 60,
71, 72, 171, 197). If initial intervention is insufficient, more tradi-
tional cancer treatment with radiation and multidrug chemother-
apy is used (135, 190).
Traditional dogma is that antiviral agents such as ganciclovir
have limited utility since they target replicating but not latent
viral infection (140, 145, 185, 201). However, there are two
lines of evidence suggesting that ganciclovir might have a role,
in concert with other therapeutic strategies. First, PTLD often
includes scattered cells expressing markers of lytic viral repli-
cation among the more predominant latently infected tumor
cell population, and animal studies show that such replicative
capability enhances tumor growth (87). Second, intriguing data
suggest that ganciclovir is rendered a more potent killer of
infected cells when combined with replication inducers (58, 65,
97, 147). This is because the EBV lytic enzyme thymidine
kinase phosphorylates ganciclovir to launch the process by
which activated ganciclovir carries out its cytotoxic effect (57).
Activated ganciclovir is a purine analog that competes with
dGTP for incorporation into nucleic acid by DNA polymerase,
where it stops strand elongation and triggers cell death. More
work is required to identify the best replication-inducing
agents to synergize with ganciclovir. Pilot studies suggest that
traditional chemotherapy or radiation could be considered (56,
97), as could demethylating agents such as azacytdine (30),
histone deacetylase inhibitors such as valproate (58, 157), or
cell-differentiating agents such as arginine butyrate (147).
Kinetics of EBV DNA Levels in Serial Specimens
Therapeutic efficacy is measured using EBV load as a
marker of tumor burden (67, 68, 71, 193, 196, 197, 206). Funk
and colleagues have mined the literature to describe the dy-
namics of how quickly EBV levels rise in PTLD patients and
how quickly levels fall during therapy (63). The kinetics seem
to depend on which organ was transplanted, which interven-
tions are used, and the specimen type that is being tested. On
average, it is estimated that transplant recipients have an EBV
DNA doubling time of about 2.6 days (standard deviation, 1.2
days), which corresponds to the doubling time of lymphocytes
undergoing cell division. The EBV DNA half-life can be as
short as 4 h on rituximab therapy, 16 h with drugs that shut
down lytic replication, or 1 day with adoptive immunotherapy
using infused cytotoxic T cells (63). Further study is needed to
determine whether relative changes in serial viral loads versus
achieving absolute cutoffs in blood or plasma viral load would
better predict disease progression or resolution.
TECHNICAL ASPECTS OF EBV LOAD ASSAYS
Blood and Plasma Are Suitable Specimen Types
Specimen types that can be obtained by noninvasive means,
such as blood and plasma, are suitable for EBV load measure-
ment. In healthy individuals, EBV DNA is usually not mea-
surable in plasma or serum, whereas it is usually amplifiable
from whole blood because the viral genome is retained after
primary infection in about 0.0001% of circulating leukocytes
(2, 12, 90). In healthy transplant recipients, baseline viral loads
tend to be higher than in normal immunocompetent hosts,
both in whole blood and in plasma, and viral loads over time
reflect the progression and resolution of PTLD (Fig. 2).
EBV DNA normally lies inside circulating B lymphocytes,
whereas patients with active EBV infection or EBV-related
PTLD also have detectable viral DNA in plasma. This extra-
cellular EBV DNA either is encapsidated, signifying that viri-
ons are being produced, or, more frequently, is naked EBV
DNA that is partially degraded and probably emanates from
dying cells (31). Nucleases may contribute to the degradation.
There is currently no consensus on whether plasma or whole
blood is the better specimen type for EBV load measurement
in transplant patients; both specimen types appear to be infor-
mative (16, 49, 98, 99, 121, 180, 193, 198, 202, 203, 205, 206).
Some investigators have applied the assay to isolated blood
mononuclear cells, but the added effort of leukocyte isolation
seems to render this method less desirable in clinical settings,
especially since results with whole blood and blood mononu-
clear cells are similar (78).
Several investigators recommend whole blood over plasma (16,
180, 202, 203). While whole blood more frequently contains am-
plifiable EBV DNA than does plasma, it would be inappropriate
to conclude that whole blood is more informative than plasma for
assessing PTLD status. Indeed, healthy transplant recipients often
have low-level EBV DNA in whole blood with or without EBV
DNA in the plasma fraction, and only a small proportion of these
patients progress to PTLD (16, 43, 78, 99, 193). A practical ad-
vantage of whole blood is that it saves labor compared to prepar-
ing plasma by centrifugation.
Two studies comparing blood or blood cells to plasma
showed greater clinical specificity when plasma was used (193,
206). The first study of pediatric solid organ transplant recip-
ients, by Wagner et al., showed some overlap between patients
with or without PTLD when blood cells were tested for EBV
levels but perfect sensitivity and specificity when plasma was
examined using a cutoff of 1,000 copies/100 l (206). A study
design flaw was that the transplant control group differed from
the PTLD group with respect to the spectrum of organs trans-
planted. The second study, by Tsai et al., evaluated 35 adult
solid organ and stem cell transplant patients who had signs and
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symptoms of PTLD (193). After clinical evaluation, 13 were
diagnosed with EBV-related PTLD and the rest served as a
control group. When applied to whole blood, the EBV PCR
assay had some false-positive results and was considered infe-
rior for ruling out PTLD compared to the plasma assay, which
was 100% specific. Both blood and plasma had similar false-
negative rates that might be attributable to location of the
tumor (e.g., brain) or timing of specimen collection (193).
Several studies showed that plasma is also more informative
than blood or blood cells for monitoring therapeutic efficacy
(134, 144, 193, 196, 206, 212).
Plasma has some practical advantages over whole blood. When
testing is delayed or when residual specimen is needed for use in
downstream quality assurance, plasma is more reliably storable
than whole blood. Automated instruments to extract nucleic acid
may accommodate some specimen types better than others (34),
and the volume of specimen required as well as the efficacy of
extraction may weigh in the decision of whether to use blood or
plasma (125). For either specimen type, it is important to perform
analytic and clinical validation studies to define assay perfor-
mance characteristics and to demonstrate that test results are
helpful in diagnosis and clinical management.
In nasopharyngeal carcinoma patients, plasma is clearly the
specimen of choice (98), and so laboratories evaluating both
transplant and nasopharyngeal carcinoma populations may ben-
efit from choosing plasma as their specimen type. In nasopharyn-
geal carcinoma, the infected malignant epithelial cells are not
seen in circulating blood, and the EBV that is measurable in
plasma is naked DNA emanating from dying tumor cells (31,
162). PTLD, on the other hand, is a neoplasm comprised of
lymphocytes that tend to circulate and turn over rapidly. How-
ever, PTLD pathology is complex: some PTLD cases may be
localized, with relatively few circulating tumor cells; some PTLD
cases express antiapoptotic factors that could render them resis-
tant to cell death and release of naked DNA; and some PTLD
cases produce virions, potentially leading to varying proportions
of EBV DNA in the cellular and plasma fractions of whole blood.
This biologic variability could complicate attempts to set a thresh-
old for diagnosing EBV-related disease.
Specimen Collection, Handling, and Storage
The preanalytic factors influencing stability of EBV DNA in
stored whole blood or plasma have not been studied in a
systematic fashion. To obtain accurate viral load results with
plasma, it is wise to promptly separate plasma from cells so
that any subsequent cell lysis does not contaminate the plasma
with intracellular viral genomes (29). Blood collection in a
“plasma preparation tube” promotes specimen integrity by cre-
ating a gel barrier between cells and plasma during centrifu-
gation, thus permitting plasma storage in the original collec-
tion tube until testing (47). (Serum is also an informative
specimen type but is not considered ideal for EBV DNA test-
ing, in part because it is prone to contamination by EBV
released from cells during clotting [2, 133, 180].)
Prior to extraction of DNA, it is recommended that plasma
be spiked with an exogenous control sequence that can later be
amplified as a control to demonstrate that extraction and am-
plification were successful (26). For whole blood, it is reason-
able to target an endogenous human gene. The advantage of
an endogenous control is that it goes through all of the same
steps as EBV DNA with respect to collection and processing,
while the disadvantage is that the control assay can detect only
gross failures in extraction or amplification since its concen-
tration varies from person to person (largely by white cell
count). In reality, any control, whether it is endogenous or
spiked, only partially reflects EBV DNA preservation and sta-
bility, given that there are four forms of naturally occurring
EBV DNA: intranuclear episomes (circular viral genomes),
linear viral genome integrated into host chromosomal DNA,
linear viral genome encapsidated in virions, and naked extra-
cellular DNA. Each form of EBV DNA is likely to be present
in variable proportions across patient specimens and is likely to
degrade at different rates ex vivo.
Real-Time Measurement of EBV DNA
Real-time PCR is an accurate and sensitive laboratory pro-
cedure for measuring viral DNA (178). While EBV transcripts
could theoretically be measured by reverse transcription-PCR
or nucleic acid sequence-based amplification (NASBA), there
is little evidence to support using RNA-based assays in the
diagnosis or monitoring of PTLD (82, 182). Therefore, this text
focuses on measuring viral load by targeting a segment of the
EBV genome in extracted DNA.
A typical real-time PCR assay utilizes a set of primers to
amplify an 80- to 100-bp conserved viral genomic sequence
combined with either an intercalating dye, a labeled primer
system (41), or a labeled internal probe (such as a TaqMan,
peptide nucleic acid, or minor groove binding probe or a pair
of fluorescence resonance energy transfer [FRET] hybridiza-
tion probes) to quantify accumulating products against a series
of standards (38, 48, 94, 115, 161, 181) (Fig. 3).
Real-time detection is more rapid and precise than tradi-
tional endpoint PCR detection, and it also minimizes the risk
of amplicon contamination since the reaction vessel may re-
main sealed after amplification. Controls are run to confirm
that negative and weakly positive specimens perform as ex-
pected. Periodic calibration of the test system is done to main-
tain accuracy and linearity (103).
Automated instruments and commercial reagents are avail-
able (Table 2). Laboratory-developed tests were recently re-
viewed by Espy et al. (48). While comparative effectiveness
studies have not been done, proficiency surveys (described
below) demonstrate that a wide variety of analytic systems can
achieve good performance. Of note, commercial reagents and
systems performed similarly to laboratory-developed tests in a
sample exchange study involving 30 EBV quantitative PCR
assays done in laboratories across North America and at two
sites in Europe (150).
Interpretation by a laboratorian combines technical knowl-
edge of relevant test systems with medical knowledge of rele-
vant clinical conditions. Interpretation typically involves exam-
ining exogenous and endogenous control assays and any
standards that were included in the run to ensure that the
assays performed as expected and then examining the analytic
findings for the patient to generate a reportable result. Exam-
ple report wording is displayed in Fig. 4. Clinical interpretation
requires knowing the clinical setting in which the test was per-
formed and evaluating the test result in the context of pertinent
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clinicopathologic findings. Evaluating serial test results requires
knowing the coefficient of variation of the assay so that rising or
falling levels can be interpreted as being significant versus lying
within the technical variability of the assay.
QUALITY ASSURANCE
Prior to implementing an EBV load assay, validation studies
are needed to demonstrate assay sensitivity, specificity, precision,
and linearity (75, 81). In addition to determining assay perfor-
mance characteristics, the laboratory must ensure that EBV load
assays perform well in clinical settings (95). “Analytic validity”
relates to reliability for measuring EBV DNA, and “clinical va-
lidity” relates to reliability for diagnosing and managing PTLD.
Guidelines for validating molecular assays were recently pub-
lished by the College of American Pathologists (95).
Optimal assay design is an important first step in developing
an analytic procedure. To overcome the impact of EBV strain
variants, conserved portions of the genome should be identi-
fied. Prior studies in which several alternative EBV load assays
were compared revealed major variations in analytic and clin-
ical sensitivity and specificity when applied to transplant pa-
tient specimens (161, 193). Targeting two independent seg-
ments of the viral genome is somewhat more informative than
targeting a single viral gene (161, 164, 193).
Validation studies should establish a list of indications for
testing and define cutoffs distinguishing normal from abnormal
results in relevant clinical settings. This is typically achieved by
comparing viral loads in patients with PTLD to those in
healthy transplant recipients and in recipients with other dis-
eases. Results in the weeks or months leading up to a diagnosis
of PTLD can help define a threshold beyond which PTLD is a
likely diagnosis, implying that a search for the site of disease
should ensue.
There is often overlap between EBV levels in healthy recip-
ients and in those who are destined to progress to PTLD, so
the threshold for initiating preemptive therapy depends on
FIG. 3. EBV load is measured by real-time PCR. Extracted DNA is placed in a thermocycler with the reagents for real-time PCR to replicate
a segment of the EBV genome in a cyclical fashion using DNA polymerase (DNA pol). To detect accumulating PCR products, the assay depicted
here uses a TaqMan probe labeled with reporter (R) and quencher (Q) dyes. As DNA pol replicates the template strand, hydrolysis of the probe
releases the reporter dye, which, when separated from the quencher, results in a measurable fluorochrome signal. As each PCR cycle ensues,
product accumulation is measured over time in the patient sample and in each of a series of standards, allowing extrapolation of the EBV load
in the patient sample. Spiking a nonhuman, nonpathogen DNA into the specimen before extraction and then amplifying the spiked DNA ensures
adequacy of extraction and lack of PCR inhibition in each patient sample.
TABLE 2. Commercial reagents and systems for real-time
measurement of EBV load
Manufacturer Country Gene target Reference(s)
Roche USA LMP2 55, 75, 86, 102, 160
Qiagen (Artus) Germany BKRF1 4, 106, 153
Argene France BXLF1 50
Amplimedical (Nanogen) Italy BKRF1 146
Nanogen (Epoch, Fisher) USA BNRF1
Attostar USA EBNA1
TIB Molbiol Germany EBNA1
EraGen USA LMP2
Sacace Italy LMP1
PrimeraDx USA Not specified
Shanghai ZJ Bio-Tech China Not specified
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clinicopathologic factors beyond EBV load. These factors in-
clude the many risk factors for PTLD (see Risk Factors for
PTLD above) and other variables such as concurrent disease
and prior response to therapy. While the laboratory should
provide guidance in the form of data supporting thresholds for
clinical intervention, the ultimate decision of when and how to
intervene is the responsibility of the attending clinician. A
clinical consultant in the laboratory must be prepared to inter-
pret test results and discuss the risks and benefits of testing as
well as use of the test in diagnosis and patient management
(95).
When an FDA-approved assay for EBV load measurement
becomes available, the process described above becomes one
of “verification” rather than validation, assuming that the test-
ing laboratory does not modify the manufacturer’s procedure.
“Verification” involves demonstrating that the assay works well
in your own hands by replicating analytic performance charac-
teristics and by vetting that the medical claims made by the
manufacturer are reasonable (95).
Proficiency Testing and Sources of
Interlaboratory Variability
Proficiency testing helps ensure that performance of an as-
say is maintained over time, and it also permits access to
compiled data on methods and results used by other testing
laboratories. There are two major purveyors of surveys for
EBV load, and their specimens and reports are available by
subscribing to the surveys (www.cap.org and www.qcmd.org
[accessed on 28 August 2009]). Frozen or lyophilized plasma
was chosen over whole blood for distribution in these profi-
ciency surveys. Proficiency testing is one of many strategies to
promote high-quality laboratory services. Ultimate responsibil-
ity lies with the laboratory director who oversees validation
work and routine testing to ensure that assays perform ade-
quately for their intended use.
Published surveys reveal a wide range of analytic test meth-
ods (81, 150). A survey of eight laboratories in the United
States found seven different EBV genomic targets and five
different instrument platforms, suggesting that most laborato-
ries are using unique test systems (81). Nevertheless, sample
exchange work demonstrates good performance across labora-
tories with respect to ranking results as high to low or unde-
tectable EBV DNA (81, 150).
Research demonstrates variable lower limits of detection
across test systems (38, 75, 81, 150, 161). Exquisite analytic
sensitivity may not be as critical for PTLD as it is for nasopha-
ryngeal carcinoma diagnosis and management (52, 75). After
all, many healthy transplant recipients have low-level EBV
viremia. Emerging evidence linking EBV loads to other aspects
of transplant patient management, such as predicting graft
dysfunction, rejection, or degree of immunosuppression, may
affect the minimal required performance characteristics of an
EBV load assay.
Surveys show that test results are quite reproducible within
a given laboratory; however, absolute values are not compara-
ble from laboratory to laboratory, since there is no agreed-
upon calibrator (150). An effort is under way to establish con-
sensus on assay calibration through the International Working
Group for the Standardization of Genome Amplification
Techniques (62). Commercial reagents that could be helpful in
standardizing quantitative EBV measurement include prod-
ucts from Advanced Biotechnologies Inc., Acrometrix, and
Zeptometrix and ATCC’s Namalwa Burkitt lymphoma cell line
containing two integrated EBV genomes per cell. Other cell
lines, such as Raji, tend to have variable EBV copy numbers
per cell because episomal viral genomes may be gained or lost
over time in cells grown in culture media.
Another source of variation across testing laboratories is the
units of measurement for reporting EBV load results. For plasma
specimens, loads are typically reported in copies per ml, whereas
whole blood results may be reported in copies per g of DNA,
copies per 100,000 leukocytes, or copies per ml (81).
FIG. 4. Generic laboratory report content that might accompany an EBV load result following testing and analytic interpretation by a
laboratory scientist.
VOL. 23, 2010 EBV LOAD IN PTLD 359
QUANTIFYING EBV DNA IN BIOPSY SPECIMENS
Biopsy tissue and cytologic specimens can be tested for EBV
DNA levels using protocols similar to those used with whole
blood (161). Fresh, frozen, or paraffin-embedded tissue is a
suitable specimen type. Because cellularity varies and because
inhibitors of amplification are common in bloody or fixed tis-
sue, it is wise to normalize EBV load to the total number of
cells evaluated using a parallel real-time PCR assay for an
endogenous human gene (161).
Normalized EBV loads are very high in tissues representing
EBER-positive PTLD, whereas a low to undetectable EBV
load characterizes EBER-negative tissues (161, 164). Results
should be interpreted in the context of histopathologic find-
ings. While negative PCR results imply the absence of EBV-
related disease, questionable or high viral loads should be
followed up with a histochemical assay to localize the virus,
such as EBER in situ hybridization (Table 3). Real-time PCR
is an advantageous screening test because (i) it is a low-cost
test compared to EBER in situ hybridization, (ii) DNA is more
stable than RNA, and (iii) detecting the viral genome renders
the test independent of which viral genes might be expressed.
Disadvantages of real-time PCR are the inability to localize
EBV to particular cell types within the lesion and the potential
for mutation or partial deletion of the viral genome to interfere
with DNA amplification.
EBV-NEGATIVE PTLD
EBV load assays are not expected to help detect or prevent
EBV-negative PTLD. Fortunately, EBV-negative PTLD is
rather uncommon, although some studies have reported rates
of up to 23%, especially in cases occurring late after transplan-
tation (128). These late-occurring EBV-negative cases may
represent more traditional forms of non-Hodgkin lymphoma.
While most PTLD cases are B cell lineage, the rare cases that
are T or NK cell lineage are more likely to be EBV negative,
and there are conflicting data on whether they are more ag-
gressive (44, 45, 155, 186). Interestingly, some of the EBV-
negative cases respond to cutting back immunosuppressive
drugs, implying that the test for EBV was false negative or that
the immune system can control certain lymphoproliferations
even when EBV is not the driving force (67). To improve
detection of EBV-related cases, it is probably worth measuring
blood or plasma EBV load in addition to performing EBER in
situ hybridization for any patient with biopsy-proven PTLD.
ON THE HORIZON
EBV load assays have rapidly been incorporated into rou-
tine medical practice because of their value in early diagnosis
of PTLD. Furthermore, EBV DNA levels reflect tumor bur-
den, so serial EBV load measurement is used to monitor the
efficacy of therapy. Further studies are needed to refine the
indications for testing and to recommended frequency of rou-
tine monitoring in high- and low-risk groups of immunosup-
pressed hosts.
The increasing availability of commercial systems facilitates
implementation of viral load assays. Efforts are under way to
make available stable reference standards so that EBV load
assays can be calibrated and made comparable across testing
laboratories. Further work is needed to optimize specimen
processing and storage procedures. Panels of assays and array-
based approaches are on the horizon as a way to possibly
improve clinical sensitivity and specificity by testing multiple
viral and human factors.
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